Claims
- 1. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds: wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF3, OCF3, CONH2, CONHR and NHCOR1; wherein R is selected from the group consisting of H, CH3, C2H5, C3H7, C4H9, CH2Ph, and CH2C6H4—F(p—); and wherein R1 and R2 are independently selected from the group consisting of H, aryl, substituted aryl, cycloaryl substituted cycloaryl, multi-ring clycloaryl, benzyl, substituted benzyl, alkyl, cycloalkyl substituted cycloalkyl, multi-ring cycloalkyl, fused-ring aliphatic, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, bicyclooctyl, bicyclononyl, substituted bicycloalknyl, adamantyl, substituted adamantyl and the like, wherein at least one of R1 and R2 are aromatic groups.
- 2. The pharmaceutical composition of claim 1, wherein the R1 and R2 substitutions are selected from the group consisting of alkyl, aryl, CF3, CH3, OCH3, OH, CN, COOR and COOH.
- 3. The pharmaceutical composition of claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.
- 4. The pharmaceutical composition of claim 3, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long-acting β2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.
- 5. A method for treating or preventing an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of claim 1.
- 6. The method of claim 5 further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.
- 7. The method of claim 6, wherein said additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long-acting β2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.
- 8. A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of claim 1.
- 9. The method of claim 8 further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.
- 10. The method of claim 9, wherein said additional ingredient is selected from the group consisting of a short-acting β2-adrenergic agonist, a long-acting β2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.
- 11. The pharmaceutical composition of claim 1, wherein the compounds are selected from the group consisting of:
RELATED APPLICATION
This application is a continuation-in-part application of U.S. application Ser. No. 09/316,870, filed on May 21, 1999, now U.S. Pat. No. 6,271,390, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Ser. No. 60/086,494, filed on May 21, 1998.
Foreign Referenced Citations (9)
Number |
Date |
Country |
0 221 346 |
May 1987 |
EP |
0 232 199A |
Aug 1987 |
EP |
0 469 477 |
Feb 1992 |
EP |
0 497 564 |
Aug 1992 |
EP |
0 700 906A |
Mar 1996 |
EP |
0 719 765 |
Jul 1996 |
EP |
WO 90 09989 |
Sep 1990 |
WO |
WO 93 25517 |
Dec 1993 |
WO |
WO 98 17267 |
Apr 1998 |
WO |
Non-Patent Literature Citations (4)
Entry |
S. Karag'ozov, Synthesis of N-acyl derivatives of 6-amino-1-4-benzodioxane STN INTERNATIONAL, vol. 39, No. 1989 pp. 5-8, Abstract only. |
Ashton et al., “Now low-density lipoprotein receptor upregulatros acting via a novel mechanism”, Journal of Medicinal Chemistry, vol. 39, Jan. 1, 1996, pp. 3343-3356. |
B. V. Cheney et al., “Structure-activity correlations for a series of antiallergy agents. 3. Development of a quantitative model”, Journal Med. Chem, vol. 26, No. 5, 1983, pp. 726-737. |
I Yildir, “Synthesis of 2-(substitutedphenyl) benzimidazole derivatives and their sedative activity: Structure-activity relationship”, Journal Fax. Gazi Uni., vol. 7, No. 2, 1990, pp. 111-114. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/086494 |
May 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/316870 |
May 1999 |
US |
Child |
09/422397 |
|
US |